GE Healthcare announced today that its Discovery* PET/CT 690 and PET VCAR 2.0 were used by Professor Patrick Flamen of the Institut Jules Bordet in Brussels in capturing the Society of Nuclear Medicine and Molecular Imaging 2013 “Image of the Year.” To see the image, visit GE Healthcare’s Newsroom.
Professor Flamen’s winning scan illustrated the effectiveness of radium-223 dichloride in treating bone metastases in breast cancer patients with bone-dominant disease. It was selected as the winning image from more than 2,000 studies.
According to SNMMI, it “chooses an image that exemplifies the most cutting-edge nuclear medicine or molecular imaging research today and that demonstrates the ability of molecular imaging to detect, diagnose and treat disease and help select the most appropriate therapy.”
“Congratulations to Professor Flamen on this stunning image demonstrating the power of molecular imaging,” said Steve Gray, president and CEO of GE Healthcare’s Molecular Imaging business. “The Institut Jules Bordet continues to be at the forefront of using this technology and GE Healthcare’s Discovery PET/CT 690 is excellent for the image quality and speed desired in these procedures.”“At the Institut Bordet, we aim to provide excellence in both clinical and research activities and we are grateful to the SNMMI for this great recognition,” said Professor Flamen. “GE has been a longtime collaborator in providing great equipment, great applications, and great support, allowing us to achieve outstanding clinical throughput with more than 5,000 PET/CT studies per year on our GE Discovery PET/CT 690.” Institut Jules Bordet, a GE PET/CT European reference center, has showcased its PET/CT imaging best practices to nuclear medicine physicians from around the world. Professor Flamen has supported the development of GE PET VCAR, an exceptional multi-modality and multi-exam comparison application to evaluate lesion metabolic activity over time. The GE Discovery PET/CT 690 is specially designed for speed, efficiency, and PET quantification accuracy. From short exam times through optimized sensitivity system design and comprehensive imaging protocols, the Discovery PET/CT 690 is the first platform focusing on quantification accuracy without compromise by providing intelligent PET and CT iterative reconstruction, respiratory motion management solutions, and integrated PET calibration technologies. PET VCAR 2.0 is the latest visualization and analytical monitoring solution featuring both PERCIST and EORTC standards helping physicians in assessing disease progression or response to therapy.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts